Will the FDA advisory panel vote in favor of GRAIL’s Galleri multi-cancer test on September 23?

Question

This market will resolve YES if… at the FDA Molecular and Clinical Genetics Panel meeting scheduled for September 23, 2026, a majority of voting members cast an affirmative vote on the panel’s principal question asking whether the available evidence supports approval, a favorable benefit-risk determination, or an equivalent recommendation permitting FDA approval of GRAIL’s Galleri test.

If FDA phrases the question as whether benefits outweigh risks, whether reasonable assurance of safety and ef

Problyx · Accepted Answer

No — the community forecast puts this at 61%.

Problyx · Answer

Yes — the community forecast puts this at 39%.